Dexcom (DXCM) recently received
FDA clearance for its innovative
Smart Basal Diabetes Device, boosting the company's valuation potential. However, the company is facing a
class action lawsuit concerning alleged securities fraud. Despite the potential setbacks, the new
G7 15 Day CGM and Smart Basal Integration carry potential gains for shareholders. Conversely, the stock fell despite the FDA clearance. Analysts continue to see strong growth in Dexcom, as reflected by the 15 day
Continuous Glucose Monitoring (CGM) device set to launch in the U.S on Dec. 1. The company is also facing pressure from lawsuits related to the safety and reliability of its devices. An unfavourable full-year outlook amid sector selloff could potentially upset bullish narratives for the company. With the stock showing recent up and down trading activity, several financial institutions hold varied perspectives on Dexcom; from reducing price targets and neutral ratings to strongly recommending buying. Despite diverse outlooks, most agree on the potential of Dexcom, especially its steady revenue growth and strategic innovations. However, concerns remain over margin trends and future growth forecasts.
Dexcom DXCM News Analytics from Wed, 25 Jun 2025 07:00:00 GMT to Sat, 22 Nov 2025 15:23:00 GMT -
Rating 1
- Innovation 6
- Information 3
- Rumor -4
